Article Sidebar

PDF
Date Published: 13/02/2023
Abstract Views: 126
Views PDF: 75
DOI: https://doi.org/10.51298/vmj.v521i1.3947
Issue
Vol. 521 No. 1 (2022)
Section
Các bài báo
How to Cite
Trần, N. T., Nguyễn, P. H., & Dương, H. T. (2023). C-MET EXPRESSION IN GASTRIC ADENOCARCINOMA. Vietnam Medical Journal, 521(1). https://doi.org/10.51298/vmj.v521i1.3947

C-MET EXPRESSION IN GASTRIC ADENOCARCINOMA

Ngọc Thụy Trần1,, Phú Hùng Nguyễn2, Hồng Thái Dương1
1 Thai Nguyen University Of Medicine And Pharmacy
2 Thai Nguyen University of Sciences

Main Article Content

Abstract

Objectives: To evaluate the level of C-met expression and its relationship with the endoscopic and histopathological features of patients with gastric antral adenocarcinoma. Subjects and methods: The study was performed on 150 cases of gastric adenocarcinoma operated at Hanoi K Hospital from January 2018 to december 2019 by cross-sectional descriptive method. Results: C-met expression was found in 51.3% of gastric adenocarcinomas. Expression of C-met in infiltrates, polyps, ulcers and polypoid was 41.7%, 50%, 51.3% and 53.7% (p > 0.05). According to Lauren's histological classification, 56,9% of intestinal type tumors  had C-met expression compared to 26.5% off diffused types and 85,7% of mixed types, respectively (p < 0.01). Accorrding to Expression of C-met was different in mixed 85.7% papillary 66.7%, mucinous 66.7%, tubular 54.5% and signet ring cell 26.5% types (p < 0.05). Expression of C-met in different grades: 48.3% of well-differentiated, 62.5%  of moderately differentiated and 43.1% of poorly differentiated tumors (p > 0.05).

Article Details

Keywords

C-met, gastric adenocacinoma, intestinal type, diffuse type

References

1. Sung H., Ferlay J. , Siegel R. L. (2021), "Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries", CA Cancer J Clin, 71(3), pp.209-249.
2. Pellino A., Riello E., Nappo F., Brignola S., Murgioni S., Djaballah S. A. et al. (2019), "Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives", World J Gastroenterol, 25(38), pp.5773-5788.
3. Anestis A., Zoi I. , Karamouzis M. V. (2018), "Current advances of targeting HGF/c-Met pathway in gastric cancer", Ann Transl Med, 6(12), pp.247.
4. Wang J., Wang S., Sun J. , Qiu L. (2021), "Expression of c-MET, EGFR and HER-2 in gastric adenocarcinoma tissue and its relationship with clinicopathological characteristics", Am J Transl Res, 13(9), pp.10856-10862.
5. Retterspitz M. F., Monig S. P., Schreckenberg S., Schneider P. M., Holscher A. H., Dienes H. P. et al. (2010), "Expression of {beta}-catenin, MUC1 and c-met in diffuse-type gastric carcinomas: correlations with tumour progression and prognosis", Anticancer Res, 30(11), pp.4635-4641.
6. Janjigian Y. Y., Werner D., Pauligk C., Steinmetz K., Kelsen D. P., Jager E. et al. (2012), "Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis", Ann Oncol, 23(10), pp.2656-2662.
7. Inokuchi M., Otsuki S., Fujimori Y., Sato Y., Nakagawa M. , Kojima K. (2015), "Clinical significance of MET in gastric cancer", World J Gastrointest Oncol, 7(11), pp.317-327.